Denise Myshko

Understanding medication utilization patterns is important for future evaluations of clinical outcomes, investigators say.

A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.

A new indication, a nonprescription switch, a recall, and new guidances round out this week’s FDA news.

Regardless of political affiliation, the public supports congressional action to allow the federal government to negotiate prices.

Although Lorbrena can improve health outcomes, it is not as cost-effective an option compared with Xalkori.

The therapy is a modified poliovirus vaccine that not only kills cancer cells but also can trigger long-term immune memory.

The Supreme Court’s dismissal of the latest challenge means patients will have access to lower-cost therapies, an advocacy group says.

The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.

Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.

Immune-related AEs can occur one to two years after treatment, are more common in combination treatments, and can be difficult to manage.

Three commercial plans now cover the corticosteroid Eysuvis.